נראה כי אירעה שגיאה במהלך טעינת העמוד הזה.
הצוות שלנו קיבל דיווח על כך, אבל אם הבעיה נמשכת, אנא צרו קשר באמצעות יישומון תמיכה במייל
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 3.2x - 3.6x | 3.4x |
| Selected Fwd EBITDA Multiple | 2.8x - 3.1x | 3.0x |
| Fair Value | ₩8,218 - ₩8,748 | ₩8,483 |
| Upside | 42.4% - 51.6% | 47.0% |
| Benchmarks | Ticker | Full Ticker |
| WooGene B&G Co., Ltd | A018620 | KOSDAQ:A018620 |
| Kyung Nam Pharm Co.,Ltd. | A053950 | KOSDAQ:A053950 |
| Enzychem Lifesciences Corporation | A183490 | KOSDAQ:A183490 |
| Seoul Pharma Co., Ltd | A018680 | KOSDAQ:A018680 |
| WITHUS PHARMACEUTICAL Co.,LTD. | A330350 | KOSDAQ:A330350 |
| Sinil Pharmaceutical Co., Ltd. | A012790 | KOSDAQ:A012790 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A018620 | A053950 | A183490 | A018680 | A330350 | A012790 | ||
| KOSDAQ:A018620 | KOSDAQ:A053950 | KOSDAQ:A183490 | KOSDAQ:A018680 | KOSDAQ:A330350 | KOSDAQ:A012790 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | -2.2% | NM- | NM- | -8.2% | -4.6% | 8.7% | |
| 3Y CAGR | 18.6% | NM- | NM- | NM- | 13.9% | 18.5% | |
| Latest Twelve Months | -40.8% | 389.8% | -33.3% | -21.3% | -22.1% | -20.0% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 7.4% | -1.8% | -44.5% | 6.4% | 12.4% | 21.1% | |
| Prior Fiscal Year | 8.1% | -1.2% | -14.8% | 6.0% | 13.4% | 21.7% | |
| Latest Fiscal Year | 7.5% | 3.7% | -16.7% | 7.5% | 9.2% | 23.3% | |
| Latest Twelve Months | 6.4% | 4.8% | -18.6% | 4.4% | 9.2% | 22.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 1.33x | 0.62x | -0.40x | 0.80x | 0.73x | 0.36x | |
| EV / LTM EBITDA | 20.9x | 13.1x | 2.1x | 18.0x | 7.9x | 1.7x | |
| EV / LTM EBIT | -115.0x | 57.1x | 1.7x | -126.6x | 13.6x | 2.4x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | 2.1x | 13.1x | 20.9x | ||||
| Historical EV / LTM EBITDA | 1.9x | 4.2x | 15.9x | ||||
| Selected EV / LTM EBITDA | 3.2x | 3.4x | 3.6x | ||||
| (x) LTM EBITDA | 17,848 | 17,848 | 17,848 | ||||
| (=) Implied Enterprise Value | 57,615 | 60,647 | 63,679 | ||||
| (-) Non-shareholder Claims * | 36,142 | 36,142 | 36,142 | ||||
| (=) Equity Value | 93,757 | 96,789 | 99,822 | ||||
| (/) Shares Outstanding | 11.4 | 11.4 | 11.4 | ||||
| Implied Value Range | 8,241.45 | 8,508.00 | 8,774.55 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 8,241.45 | 8,508.00 | 8,774.55 | 5,770.00 | |||
| Upside / (Downside) | 42.8% | 47.5% | 52.1% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A018620 | A053950 | A183490 | A018680 | A330350 | A012790 | |
| Enterprise Value | 70,672 | 31,246 | (30,049) | 41,701 | 74,709 | 29,499 | |
| (+) Cash & Short Term Investments | 18,691 | 44,411 | 112,273 | 10,356 | 23,055 | 35,700 | |
| (+) Investments & Other | 7,743 | 14,674 | 1,041 | 3 | 10,070 | 798 | |
| (-) Debt | (33,092) | (35,707) | (4,120) | (17,899) | (22,812) | (356) | |
| (-) Other Liabilities | (39,576) | 0 | (1,202) | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 24,439 | 54,625 | 77,942 | 34,162 | 85,022 | 65,641 | |
| (/) Shares Outstanding | 28.9 | 78.1 | 77.6 | 11.7 | 13.2 | 11.4 | |
| Implied Stock Price | 846.00 | 699.00 | 1,004.00 | 2,930.00 | 6,440.00 | 5,770.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 846.00 | 699.00 | 1,004.00 | 2,930.00 | 6,440.00 | 5,770.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |